"label","id","identifier","uuid:ID","name","description","instanceType","text"
"","EligibilityCriterion_1","1","5e566202-1afc-496c-a0c7-43f7760ca91c","Age Criteria","The study age criterion","EligibilityCriterion","Subjects shall be between [min_age] and [max_age]"
"","EligibilityCriterion_2","2","00ab1d68-36c2-49e2-a1b2-7711790dd0a0","Pop Criteria","The study population criterion","EligibilityCriterion","[StudyPopulation] as defined by the NINCDS and the ADRDA guidelines (Attachment LZZT.7)"
"","EligibilityCriterion_3","3","593fa1cd-c6c3-425e-bdc6-bd280074389c","Diag Criteria","The study diagnosis criterion","EligibilityCriterion","[Activity1] score of 10 to 23"
"","EligibilityCriterion_4","9","99b2be5e-2bf5-4eb0-9e1e-207cadf259e4","Previous Criteria","The previous xanomeline TTS criterion","EligibilityCriterion","Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline."
